Published in Lab Business Week, September 23rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at MacroChem Corporation.
Report 1: MacroChem Corporation (OTCBB: MACM) announced that it has signed an exclusive option to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation (Genaera).
"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week